Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: First-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3718-3726

  Modest, Dominik P ^a,c   Stintzing, Sebastian ^a,c   Von Weikersthal, Ludwig Fischer ^d   Decker, Thomas ^e   Kiani, Alexander ^f   Vehling Kaiser, Ursula ^g   Al Batran, Salah Eddin ^h   Heintges, Tobias ⁱ   Lerchenmüller, Christian ^j   Kahl, Christoph ^k   Seipelt, Gernot ^l   Kullmann, Frank ^m   Stauch, Martina ⁿ   Scheithauer, Werner ^q   Held, Svantje ^o   Möhler, Markus ^p   Jung, Andreas ^b,c   Kirchner, Thomas ^b,c   Heinemann, Volker ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Gesundheitszentrum St Marien   (Germany)

^e Oncological Practice   (Germany)

^f INSTITUTE OF PATHOLOGY   (Germany)

^g Oncological Practice   (Germany)

^h KRANKENHAUS NORDWEST   (Germany)

ⁱ Städtisches Klinikum Neuss   (Germany)

^j Hematology and Oncology Practice   (Germany)

^k Klinikum Magdeburg   (Germany)

^l Oncology Practice   (Germany)

^m Klinikum Weiden   (Germany)

ⁿ Oncologic Practice   (Germany)

^o CLINASSESS GMBH   (Germany)

^p JOHANNES GUTENBERG UNIVERSITY   (Germany)

^q MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL SURGERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAZARD RATIO; HUMAN; HYPERTHERMIC THERAPY; INTENTION TO TREAT ANALYSIS; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ABLATION; WILD TYPE; ADULT; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84947436561     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.2887     Document Type: Article

References (19)

1. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
2. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 22:1535-1546, 2011
3. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034, 2013
4. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
5. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
6. Schmoll HJ, Van Cutsem E, Stein A, et al: ESMO consensus guidelines for management of patients with colon and rectal cancer: A personalized approach to clinical decision making. Ann Oncol 23:2479-2516, 2012
7. Venook AP, Niedzwiecki D, Lenz H.-J., et al: CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wildtype (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32:4s, 2014 (suppl 15s; abstr LBA3)
8. Heinemann V, von Weikersthal LF, Decker T, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 15:1065-1075, 2014
9. Sclafani F, Cunningham D: Cetuximab or bevacizumab in metastatic colorectal cancer? Lancet Oncol 15:1040-1041, 2014
10. Koopman M, Simkens L, May A, et al: Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). J Clin Oncol 32, 2014 (suppl; abstr LBA388)
11. Hegewisch-Becker S: Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone or no treatment, following a 24-week first-line induction with FP, oxaliplatin (Ox) and Bev for patients with metastatic colorectal cancer: Mature data and subgroup analysis of the AIO KRK 0207 phase III study. Ann Oncol 25, 2014 (suppl 4; abstr)
12. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007
13. Peeters M, Price TJ, Cervantes A, et al: Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 25:107-116, 2014
14. Sobrero AF, Maurel J, Fehrenbacher L, et al EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311-2319, 2008
15. Van Cutsem E, Tabernero J, Lakomy R, et al Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506, 2012
16. Bennouna J, Sastre J, Arnold D, et al: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 14:29-37, 2013
17. Ciardiello F, Bianco R, Caputo R, et al: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10:784-793, 2004
18. Viloria-Petit A, Crombet T, Jothy S, et al: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61:5090-5101, 2001
19. Hecht JR, Cohn AL, Dakhil SR, et al: SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC). J Clin Oncol 31:233s, 2013 (suppl 15s; abstr 3616)